As Olympics loom, Japanese approval of Moderna's Covid-19 vaccine unlikely till May
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
FRIDAY, MAY 27, 2022
FRIDAY, MAY 27, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
As Olympics loom, Japanese approval of Moderna's Covid-19 vaccine unlikely till May

Coronavirus chronicle

Reuters
07 January, 2021, 04:55 pm
Last modified: 07 January, 2021, 04:58 pm

Related News

  • Tokyo Olympics in the eyes of an expatriate Bangladeshi photographer
  • Tunisia, Japan celebrate unexpected gold, Australia smash world record
  • Olympics Swimming: The Russians are back - and hunting gold
  • Tokyo Olympics: Ruman, Diya eliminated from recurve mixed event
  • China's Yang wins battle of nerves to claim Tokyo's first gold

As Olympics loom, Japanese approval of Moderna's Covid-19 vaccine unlikely till May

With an eye on the Olympics due to start in late July, Japan has secured rights to at least 540 million doses of Covid-19 vaccines from several Western developers, the biggest quantity in Asia and more than enough for its 126 million population

Reuters
07 January, 2021, 04:55 pm
Last modified: 07 January, 2021, 04:58 pm
The giant Olympic rings are seen through at the waterfront area at Odaiba Marine Park after postponing Games due to the outbreak of coronavirus disease (Covid-19), in Tokyo, Japan March 25, 2020. Photo: Reuters/Issei Kato
The giant Olympic rings are seen through at the waterfront area at Odaiba Marine Park after postponing Games due to the outbreak of coronavirus disease (Covid-19), in Tokyo, Japan March 25, 2020. Photo: Reuters/Issei Kato

Moderna Inc's Covid-19 vaccine is unlikely to win approval in Japan until May due to requirements for local clinical trials, the distributor said, casting doubt over a nationwide vaccination rollout before the summer Tokyo Olympics.

With an eye on the Olympics due to start in late July, Japan has secured rights to at least 540 million doses of Covid-19 vaccines from several Western developers, the biggest quantity in Asia and more than enough for its 126 million population.

But Tokyo faces a major regulatory bottleneck due to requirements for local clinical trials before requesting approval. Several other countries have fast-tracked the review process to expedite mass inoculations.

A Japanese trial of the Moderna vaccine, which has already won approval in the United States, Europe, Canada and Israel, is due to start this month.

Masayuki Imagawa, the head of the Japan vaccine business for Takeda Pharmaceutical Co, told Reuters it would likely take several more months to complete the trial and said securing approval in May was "the best case scenario".

Takeda, Japan's biggest drugmaker, is a critical component to Prime Minister Yoshihide Suga's aim to have enough vaccines for the population by June before the Summer Games, currently scheduled to start on July 23.

The company is handling domestic approval and imports of the Moderna shot and local production of Novavax Inc's vaccine, whose development and approval in Japan is further off.

Moderna did not immediately respond to an emailed request for comment.

LOGISTICAL HURDLES

A Covid-19 vaccine developed by Oxford University and AstraZeneca Plc is also being trialed in Japan, leaving a shot developed by Pfizer Inc and BioNTech the only one currently under regulatory review in the country.

Japan has arranged to buy 120 million doses each from Pfizer and AstraZeneca. Through Takeda, it will secure 50 million doses of the Moderna vaccine and up to 250 million of the Novavax formula.

Leaving regulatory hurdles aside, production arrangements and logistical challenges could also complicate vaccine rollouts, as Japan is gripped by a third wave of the pandemic that has been the widest and deadliest yet.

New daily infections nationwide have hit fresh records in recent days, exceeding 7,000 on Thursday. The prime minister has declared a month-long state of emergency in Tokyo and three neighbouring prefectures.

"To achieve the needed production volume, there are various factories to be contracted and tech transfers to be done all over the world," said Imagawa. "And whether that can all really come together to secure enough supply is a remaining challenge."

Pfizer carried out combined Phase I and II trials of its vaccine candidate in Japan in the autumn and said in late December it had applied for approval in Japan for its vaccine, which at the time was already being distributed in Britain and the United States.

Suga said he hoped administering the Pfizer shot could start by the end of February.

AstraZeneca began Japan trials of its vaccine in September but has not yet applied for approval, even as it was approved in India, Britain, Argentina and El Salvador and filed to regulators in South Korea and Mexico.

An AstraZeneca spokeswoman declined to comment on the vaccine's approval or distribution timeline in Japan, citing confidentiality with the government.

Takeda hoped to begin clinical trials of the Novavax candidate next month and, upon approval, it would be mass produced at the company's facility in Yamaguchi prefecture, Imagawa said.

World+Biz

tokyo olympics 2020

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Ceylon Petroleum Corp.’s oil refinery in Sapugaskanda, Sri Lanka.Photographer: Ishara S.. Kodikara/AFP/Getty Images
    Bankrupt Sri Lanka takes Russia oil as fuel crisis persists
  • Infographic: TBS
    Census in monsoon: Tk12.85cr to be spent on umbrellas, waterproof bags
  • PID photo
    Asia must combine forces for a better future: PM Hasina

MOST VIEWED

  • People in protective suits cross a street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    Shanghai heading out of lockdown but China still lost in economic gloom
  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Tightening Covid net, Beijing deals out punishments, stark warnings
  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing ramps up Covid quarantine, Shanghai residents decry uneven rules
  • A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters
    Pfizer says 3 Covid shots protect children under 5
  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing urges millions to keep working from home amid Covid outbreak menace
  • Picture: PTI
    Saudi Arabia bans travel to India, 15 other countries over Covid outbreaks

Related News

  • Tokyo Olympics in the eyes of an expatriate Bangladeshi photographer
  • Tunisia, Japan celebrate unexpected gold, Australia smash world record
  • Olympics Swimming: The Russians are back - and hunting gold
  • Tokyo Olympics: Ruman, Diya eliminated from recurve mixed event
  • China's Yang wins battle of nerves to claim Tokyo's first gold

Features

The taboo of dining out alone

The taboo of dining out alone

6h | Food
The perfect time for newborn photography is between the first five and 14 days when a baby’s bones are the most malleable for posing. Photo: Courtesy

Is there a market for newborn photography in the country? Studio Picturerific says yes

6h | Panorama
Pakistan finds itself in political turmoil again as Imran Khan pushes for immediate general elections. Photo: Reuters

Supreme Court of Pakistan: Now a candle in the dark

7h | Analysis
Indulge in Momium’s guilt-free dips and spreads

Indulge in Momium’s guilt-free dips and spreads

7h | Food

More Videos from TBS

Fear of food crisis sets across the globe

Fear of food crisis sets across the globe

2h | Videos
Is Mushfiq refraining from self-destructive shots?

Is Mushfiq refraining from self-destructive shots?

2h | Videos
Kanak is ahead of everyone in Guinness Book

Kanak is ahead of everyone in Guinness Book

7h | Videos
What should your CV cover letter look like?

What should your CV cover letter look like?

9h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
Bangladesh at risk of losing ownership of Banglar Samriddhi
Bangladesh

Bangladesh at risk of losing ownership of Banglar Samriddhi

3
Corporates go cashless…tax cut on cards
NBR

Corporates go cashless…tax cut on cards

4
Photo: Courtesy
Panorama

Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
Illustration: TBS
Banking

Let taka slide

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab